Accessibility Menu
Inhibikase Therapeutics logo

Inhibikase Therapeutics(NASDAQ) IKT

Market Cap$326.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-96%
5 Year-81%
1 Year+59%
1 Month+19%
$2.46
+2.08%
+0.05Today
After hours$2.47+$0.01 (+0.41%)
Inhibikase Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.472026-08-07
Inhibikase Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.3%USD 2.182026-07-31
1 month+19.32%USD 2.072026-07-08
3 month+19.9%USD 2.062026-05-08
Year to date+20.49%USD 2.052025-12-31
1 year+59.35%USD 1.552025-08-07
3 year+2.92%USD 2.402023-08-08
5 year-80.94%USD 12.962021-08-06
Since inception-95.84%USD 59.402020-12-23

Inhibikase Therapeutics Financials at a Glance

Market Cap

$326.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$50.96M

EPS (TTM)

-$0.43

P/E Ratio

-5.69

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$2.46

Volume

386,846.405

Open

$2.38

Previous Close

$2.47

Daily Range

$2.38 - $2.48

52-Week Range

$1.33 - $2.53

Estimated Earnings Date

Aug 13, 2026

IKT News

Foolcom-Featured.png

Inhibikase Posts Wider Loss in Q2

Motley Fool Markets TeamAug 14, 2025

IKT: Motley Fool Moneyball Superscore

40

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inhibikase Therapeutics

Inhibikase develops medicines for people with rare lung and brain diseases. Its main drugs aim to improve daily life for patients with serious conditions. The company focuses on treatments that target disease causes, not just symptoms.

What’s in the Medicine Cabinet?

  • IKT-001: Oral drug for pulmonary arterial hypertension (PAH), a rare lung disease; no revenue contribution yet.
  • IkT-148009: Small molecule for Parkinson’s disease and related disorders; outlicensed in 2025, no current revenue.
  • IkT-001Pro: Preclinical drug for blood and stomach cancers, designed to reduce side effects; no revenue yet.
  • Research Programs: Early-stage work on other neurological diseases; no commercial sales.

Growth Spurts and Strategic Moves

  • Acquired CorHepta Pharmaceuticals in 2025, expanding its drug pipeline and scientific team.
  • Outlicensed IkT-148009 to ABLi Therapeutics in 2025, securing milestone payments and royalties.
  • Launched global Phase 3 trial for IKT-001 in PAH in 2025, with up to 180 sites worldwide.
  • Raised $115M in a public offering in November 2025 and $99.6M in a private placement in October 2024.
  • Formed research partnerships with Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University.

Why Inhibikase Is a Bit Different

The company uses prodrug technology to improve drug tolerability and dosing. It focuses on disease-modifying therapies, aiming to treat root causes. Patent protection and orphan drug strategies help secure its market position.

Five Things You Need to Know

  • Revenue was $0 in Q3 2025, unchanged from Q3 2024, down 100% from Q3 2023.
  • Net loss was $13M in Q3 2025, up 127.6% from Q3 2024.
  • Operating loss was $12M in Q3 2025, up 106.5% from Q3 2024.
  • Cash, cash equivalents, and marketable securities totaled $178.8M as of December 31, 2025.

Bottom Line

Inhibikase has shifted from Parkinson’s research to focus on rare lung diseases. The company relies on partnerships, licensing, and external funding to advance its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

35

CEO

Mark T. Iwicki, MBA

Website

www.inhibikase.com

Headquarters

Wilmington, DE 19801, US

IKT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-41.31%

Return on Capital

-30.06%

Return on Assets

-29.40%

Earnings Yield

-17.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$326.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

132.03M

Volume

386.85K

Avg. Volume

857.73K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$55.59M

EBITDA

-$53.92M

Operating Cash Flow

-$35.74M

Capital Expenditure

-$452.02K

Free Cash Flow

-$36.19M

Cash & ST Invst.

$170.37M

Total Debt

$0.00

Inhibikase Therapeutics Performance Analysis

Inhibikase Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 123,440-96.0%
20232023-12-31USD 260,501111.0%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Inhibikase Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Inhibikase Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.30-11.8%
20232023-12-31USD -3.57-17.0%
20242024-12-31USD -1.16-67.5%
20252025-12-31USD -0.49-57.7%
Inhibikase Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3026.7%
Q32025-09-30-18.2%
Q42025-12-31N/A
Q12026-03-31-30.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$326.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.32M

N/A

Employees

35

N/A

Net Income

-$16.38M

-19.8%

EBITDA

-$16.38M

-4.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$170.37M

+82.8%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-29.40%

N/A

Return on Invested Capital

-33.17%

N/A

Free Cash Flow

-$12.06M

-193.9%

Operating Cash Flow

-$12.06M

-193.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TTRXTurn Therapeutics Inc.
$10.41+8.32%
AGENAgenus Inc.
$6.96-7.08%
GLSIGreenwich LifeSciences, Inc.
$14.36+0.84%
SRZNSurrozen, Inc.
$25.62+18.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About IKT

What is the current price of Inhibikase Therapeutics?

Inhibikase Therapeutics is trading at $2.47 per share.

What is the 52-week range for Inhibikase Therapeutics?

Over the past 52 weeks, Inhibikase Therapeutics has traded between $1.33 and $2.53.

How much debt does Inhibikase Therapeutics have?

As of the most recent reporting period, Inhibikase Therapeutics reported total debt of $0.00.

How much cash does Inhibikase Therapeutics have on hand?

Inhibikase Therapeutics reported $49.57M in cash and cash equivalents in its most recent financial results.

What is Inhibikase Therapeutics’s dividend yield?

Inhibikase Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services